Urine Oxalate and Citrate
EPTIS factsheet 142599 | Last revision 2024-05-22 | URL: https://www.eptis.bam.de/pts142599 https://www.eptis.bam.de/pts142599
| PT provider | ||||||||||
| PT provider | Weqas Weqas | |||||||||
| Based in | United Kingdom | |||||||||
| Language(s) | ||||||||||
| Remarks | The amounts of oxalate and citrate excreted in urine and their urinary concentrations are important risk factors for the development of kidney stones. Citrate in the urine has long been recognized as an inhibitor of calcium salt crystallization and patients having low citrate levels (hypocitraturia) are at increased risk of kidney stone formation. There are several metabolic disorders associated with low urinary citrate concentrations, any condition which lowers renal tubular pH or intracellular pH, may decrease citrate, e.g. metabolic acidosis, increased acid ingestion, hypokalaemia or hypomagnesaemia. This programme is designed to span both the analytical and clinically relevant range for the diagnosis and management of hyperoxaluria and hypocitraturia. The samples consist of challenging samples at low concentration for citrate as well as a panel of 6 linearly related pools produced from urine donations spiked with oxalate and citrate to span the analytical range. Each sample is distributed on 6 occasions with a minimum of 36 samples distributed over the year. The programme assesses both laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Liquid human serum samples require no pre-analytical preparation. - Samples cover both analytical and clinically relevant range. - Challenging samples at low citrate concentration. - Linearly related panel assists with your compliance to ISO 15189. For more information: https://www.weqas.com/services/eqa/oxalate-citrate/ or contact@weqas.com | |||||||||
| Keywords | ||||||||||
| Product groups |
Health care / medical devices
|
|||||||||
| Testing fields |
Medical analysis
|
|||||||||
| Technical details | ||||||||||
|
||||||||||
| Aims of the PT scheme | ||||||||||
| Target group of participants | The programme assesses both laboratory and method performance, including linearity, bias, within and between batch imprecision. | |||||||||
| Linked to specific legislation / standards | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | |||||||||
| Additional, subsidiary aims | validation of testing methods | |||||||||
| Number of participants | ||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 |
|||||||||
| Operation is commissioned / requested by | ||||||||||
| Fees and frequency | ||||||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||
| Regularly operated | Yes (Frequency: Monthly. Samples: 3 x 2.5mL.) | |||||||||
| Year of first operation | 2003 | |||||||||
| Contact details of the PT provider | ||||||||||
| Provider | Contact person | |||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.